FAP Ligands for Targeted Drug Delivery

The patent introduces FAP-specific ligands as intermediary molecules that selectively bind to FAP-expressing tumor cells. These ligands serve as mediators between the cytotoxic payload and the target cells, enabling selective delivery. The ligand-FAP binding complex acts as an intermediary system that directs the therapeutic agent specifically to malignant cells while sparing healthy tissue, thereby resolving the contradiction between achieving tumor efficacy and reducing side-effects.

The invention applies local quality by concentrating the therapeutic effect specifically at the tumor site through FAP-targeted ligand binding. The drug conjugate exhibits different biological properties in different locations: high affinity and stability at the FAP-positive tumor site, and rapid clearance from healthy tissues. This spatial differentiation of drug properties enables selective toxicity toward cancer cells while preserving healthy cells, directly addressing the specificity-safety contradiction.

The FAP-specific ligand serves as an intermediary that facilitates efficient drug accumulation at the tumor site. By binding with high affinity to FAP on tumor cell surfaces, the ligand acts as a targeting vehicle that directs the cytotoxic payload specifically to the tumor. This intermediary mechanism overcomes the inefficient passive distribution of conventional chemotherapy, enabling concentrated drug delivery at the target site and thereby improving both accumulation and therapeutic productivity.

The invention replaces the passive mechanical diffusion system of conventional chemotherapy with an active biological targeting system. Instead of relying on random distribution and passive accumulation, the drug conjugate uses specific ligand-FAP binding interactions to actively navigate to and accumulate at the tumor site. This substitution of passive mechanical delivery with active biological recognition dramatically improves drug concentration at the tumor while maintaining systemic administration, thus enhancing both accumulation and therapeutic efficacy.

The invention applies parameter changes by systematically optimizing the chemical structure of the ligand to achieve the desired balance between penetration speed and binding affinity. By modifying molecular weight, hydrophobicity, charge distribution, and functional group composition of the small organic ligand, the researchers tuned the pharmacokinetic and pharmacodynamic parameters to achieve rapid tumor penetration while maintaining high FAP binding specificity. This parameter optimization approach enables small ligands to overcome their inherent limitations and achieve both fast delivery and high target engagement.

The patent employs composite material design by combining the FAP-specific ligand with the cytotoxic payload through a designed linker structure. This composite small molecule conjugate integrates the targeting functionality of the ligand with the therapeutic functionality of the payload, creating a unified molecule that achieves both rapid penetration and high specificity. The composite structure allows the small ligand to maintain its size advantage for fast penetration while the attached payload provides the therapeutic effect, and the specific ligand-FAP binding ensures targeted delivery, thereby achieving both speed and precision requirements.